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Abstract
Erythropoietin (EPO) is a cytokine mainly induced in hypoxia conditions. Its major production site is the kidney. EPO
primarily acts on the erythroid progenitor cells in the bone marrow. More and more studies are highlighting its secondary
functions, with a crucial focus on its role in the central nervous system. Here, EPO may interact with up to four distinct
isoforms of its receptor (erythropoietin receptor [EPOR]), activating different signaling cascades with roles in neuropro-
tection and neurogenesis. Indeed, the EPO/EPOR axis has been widely studied in the neurodegenerative diseases field. Its
potential therapeutic effects have been evaluated in multiple disorders, such as Alzheimer’s disease, Parkinson’s disease,
amyotrophic lateral sclerosis, spinal cord injury, as well as brain ischemia, hypoxia, and hyperoxia. EPO is showing great
promise by counteracting secondary neuroinflammatory processes, reactive oxygen species imbalance, and cell death in
these diseases. Multiple studies have been performed both in vitro and in vivo, characterizing the mechanisms through which
EPO exerts its neurotrophic action. In some cases, clinical trials involving EPO have been performed, highlighting its ther-
apeutic potential. Together, all these works indicate the potential beneficial effects of EPO.
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Introduction
Erythropoietin (EPO) is a 30-kDa molecular weight gly-
coprotein of 165 amino acids, coded by the EPO gene,
located on Chromosome 7 (Law et al., 1986). EPO
presents one small O-linked glycan and three tetra-
antennary N-linked polysaccharide units, fundamental
for its secretion, molecular stability, and binding to its
receptor, erythropoietin receptor (EPOR; Tsuda et al.,
1988). EPO is a type I cytokine essential for erythroid
development and maturation (Brines and Cerami, 2005).
Its expression is canonically induced by both hypoxia-
inducible factor-1 (HIF-1) and HIF-2 (Keswani et al.,
2011; Maiese et al., 2012), transduction factors sensitive
to hypoxia and anemia. EPO expression is thus activated
during the hematopoiesis process, where it coordinates
the hormonal modulation on the hematopoietic system
(Jelkmann, 2001). EPO’s main site of production changes
throughout human life. During fetal development, blood
cells are produced in the liver, and EPO is produced
locally in this organ. After birth, the major EPO’s pro-
duction site becomes the kidney peritubular cells
(Jelkmann, 2001). Secondary EPO production sites
have been described, and EPO’s expression in organs
other than the kidney accounts for about 15% to 20%
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of the total production throughout the organism (Ponce
et al., 2013). Although the kidney peritubular interstitial
cells remain the main site of EPO production and secre-
tion, a more pleiotropic role for EPO has been demon-
strated in studies showing its expression in the
endothelium and in the central nervous system (CNS;
Anagnostou et al., 1990; Digicaylioglu et al., 1995;
Marti et al., 1996). Within the CNS, EPO’s production
and secretion has been demonstrated in the hippocam-
pus, cortex, and midbrain. Furthermore, in the develop-
ment of the brain and vascular system, EPO has been
demonstrated to have a relevant function in promoting
and stimulating neurogenesis (Shingo et al., 2001;
Lombardero et al., 2011). Moreover, EPO limits cell
injury and blocks the production of reactive oxygen
species (ROS; Dang et al., 2010). Its neuroprotective
effect and its role in counteracting oxidative stress indi-
cate a potential beneficial effect for the molecule in
the treatment of neurodegenerative diseases. EPO is
currently the most sold biopharmaceutical product
worldwide according to the Food and Drug
Administration, and in particular, recombinant human
EPO (rhEPO) is indicated in the treatment of anemic
patients and diseases associated with low concentrations
of EPO in plasma (European Medicines Agency; U.S.
Food and Drug Administration; Ng et al., 2003).
Remarkably, these patients show significant cognitive
improvements, leading to the conjecture that EPO
could be used for the treatment of neurodegenerative
diseases (Sargin et al., 2011).
EPOR: Different Localizations for a Pleiotropic Function
EPOR presents a 225-amino acids extracellular domain,
a single transmembrane section of 23 amino acids, and a
cytoplasmic domain of 235 amino acids (Constantinescu
et al., 1999; Marcuzzi et al., 2016). The extracellular com-
ponent presents two domains, D1 and D2, both neces-
sary for EPO’s binding (de Vos et al., 1992; Matthews
et al., 1996). In the hematopoietic system, EPO’s binding
to its receptor leads to homodimerization, with the acti-
vation of the associated Janus tyrosine kinase 2 (JAK2)
and secondary signaling molecules, such as the signal
transducer and activator of transcription 5 (STAT5),
phosphatidylinositol 3-kinase (PI3K), and mitogen-
activated protein kinase (MAPK; Darnell et al., 1994;
Constantinescu et al., 1999). This signaling leads to dif-
ferentiation and lineage commitment of erythroid
colony-forming unit and burst-forming unit progenitors,
indicating that EPO’s signaling is necessary for red cell
maturation (Constantinescu et al., 1999; Brines and
Cerami, 2005; Richmond et al., 2005).
In the past 20 years, many studies have reported var-
ious nonhematopoietic functions of EPO and EPOR in
endothelial cells, myoblasts differentiation, colon, and in
the CNS (Anagnostou et al., 1990; Ogilvie et al., 2000;
Arcasoy et al., 2003; Brines and Cerami, 2005; Maiese
et al., 2012). Interestingly, it has been demonstrated that
biologically active EPO is synthesized in the brain with
important roles in neurodevelopment and in the modu-
lation of neurotransmission (Masuda et al., 1994;
Digicaylioglu et al., 1995). As EPOR is detected at the
embryonic state in neurons and astrocytes of the brain
and spinal cord, EPO seems to have an important func-
tion in the brain already in the fetal stage (Juul et al.,
1999). Linked to this finding, it has been demonstrated
that EPOR is present in rats’ oligodendrocytes and astro-
cytes in culture and that rhEPO administration enhances
their maturation and proliferation, suggesting that the
EPO/EPOR interaction is important in tissue repair
after damage (Sugawa et al., 2002).
The different functions exerted in the CNS with
respect to the hematopoietic system could be explained
by the fact that EPOR occurs in at least four different
isoforms, expressed specifically in different tissues
(Ostrowski and Heinrich, 2018; Figure 1).
1. The canonical isoform, which is mainly present in the
hematopoietic system, is present in the brain
(Constantinescu et al., 1999). EPO’s binding to
EPOR leads to the formation of a homodimer,
which phosphorylates JAK2 and activates the subse-
quent intracellular pathway that enables erythroid dif-
ferentiation and maturation (Constantinescu et al.,
1999). In the brain, the canonical isoform activation
by EPO mediates EPO’s action in neuroinflammation
and hypoxia (Lombardero et al., 2011).
2. The second isoform of EPOR is involved in neural
tissue protection (Brines et al., 2004). In this case,
the EPOR monomer interacts with the beta common
receptor bcR (CD131), a typical receptor subunit of
interleukin 3, interleukin 5, and granulocyte-
macrophage colony stimulating factor (Brines and
Cerami, 2005). The most accredited hypothesis is
that the dimer formation results in a specific tissue—
protective receptor. The activation of this receptor
seems to activate the same JAK2 signaling pathway
as the canonical homodimer (Brines et al., 2004;
Brines and Cerami, 2012).
3. The third isoform of the receptor has been found in
dopaminergic neurons of the substantia nigra, where
EPOR results altered in the extra regional domain,
being shorter than the full form (Marcuzzi et al.,
2016). EPOR truncated isoform does not implicate
STAT phosphorylation, suggesting the presence of
another mechanism of action not yet characterized
(Marcuzzi et al., 2016). This could be useful for the
identification of possible drugs targeting specifically
this isoform.
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4. Last, an extracellular soluble version of the receptor
has been shown to occur in the murine brain. This
isoform interacts with EPO, with no activation of
any downstream mediator. This leads to a reduced
bioavailability of EPO, thereby limiting its interaction
with other isoforms of EPOR. The expression of this
isoform results downregulated during hypoxia, which
triggers a mechanism that opposes full-length EPOR
(Soliz et al., 2007).
Even if the presence of all these different isoforms
paves the way for new interesting mechanisms through
which EPO could exert its function in the brain, many
questions remain unanswered. Indeed, it is necessary
to investigate how EPO’s binding to each isoform acti-
vates a specific intracellular pathway, modulating
the expression of target genes. Once these mechanisms
have been elucidated, it will be possible to develop
new isoform-selective drugs, resulting in a more
specific therapy.
EPO Is Involved in Canonical Cellular
Pathways of Neurodegeneration
EPO’s production and function in the brain are now
widely investigated. Multiple studies in vitro and in pre-
clinical in vivo models have highlighted the beneficial
effects of the cytokine. EPO exerts a neurotrophic
action on multiple pathways involved in neurodegenera-
tion (Figure 2; Bartesaghi et al., 2005; Maiese et al., 2012;
Chong et al., 2013; Bond and Rex, 2014; Jelkmann, 2016;
Herna´ndez et al., 2017).
Regulation of Cellular Proliferation: Effects on
Neurogenesis and Apoptosis
Considering the fact that EPO’s primary function is the
regulation of the development and maturation of ery-
throid cells, it is worth investigating whether a similar
function could be exerted by targeting neuronal cells.
EPO’s effects on neurogenesis are now widely studied,
Figure 1. Different isoforms of EPOR in the CNS. In its canonical isoform, EPO’s binding leads to the homodimerization of the receptor
and phosphorylation of JAK2 molecules. This activates specific intracellular pathways (STAT-PI3K-MAPK). In the second case, the EPOR
monomer interacts with the beta common receptor bcR activating the JAK2 pathway. A third isoform of the receptor occurs in dopa-
minergic neurons of the substantia nigra, where EPOR results altered in the extra regional domain. In this case, the isoform is shorter than
the full form, leading to the lack of STAT phosphorylation. Last, a soluble version of the receptor has been found in the murine brain. This
isoform interacts with EPO, with no activation of any downstream pathway. This leads to a reduced availability of EPO, thereby reducing its
interaction with other isoforms of EPOR. Made in !BioRender—biorender.com
aa¼ amino acids; EPOR¼ erythropoietin receptor; JAK2¼ Janus tyrosine kinase 2; MAPK¼mitogen-activated protein kinase;
PI3K¼ phosphatidylinositol 3-kinase; STAT¼ signal transducer and activator of transcription.
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representing a key pathway through which EPO could
exert its neuroprotective roles in neurodegenerative dis-
eases (Chong et al., 2013). Furthermore, the ablation of
the canonical isoform of EPOR in knockout murine
models results in massive apoptosis, associated with a
reduction of neural progenitor cells and death at
Embryonic Day 13.5 (Yu et al., 2002). As EPO’s effects
on neurogenesis are pleiotropic, they may concern neural
precursors cells (NPCs) of different origin as well and
may include increased proliferation of progenitors with
accelerated differentiation, a process described in hypox-
ic mesencephalic precursors cells (Studer et al., 2000).
Likewise, similar effects of EPO in neural stem cells iso-
lated from both murine E14 ganglionic eminence and
adult subventricular zone have been characterized
(Shingo et al., 2001). Furthermore, EPO seems to play
a pivotal role in the enhancement of hippocampal neuro-
genesis (Osredkar et al., 2010; Hassouna et al., 2016).
EPO-led neurogenesis was also observed in spinal cord-
derived neural stem cells (Zhang et al., 2018). EPO can
also indirectly promote neurogenesis through the activa-
tion of brain-derived neurotrophic factor (BDNF; Wang
et al., 2004). Besides increasing neurogenesis, EPO can
inhibit the apoptosis process (Merelli et al., 2015). The
activation of EPOR downstream molecules JAK2 and
PI3K, together with the regulation of the apoptotic pro-
teins Bad and Bcl-xL, leads to a decrease in the apoptosis
process (Bartesaghi et al., 2005; Shang et al., 2012;
Herna´ndez et al., 2017).
Modulation by Oxygen: Implications of Hypoxia and
ROS Formation
EPO is perhaps the first ever protein whose expression
was reported to be oxygen-dependent (Jelkmann, 2007).
The discovery of the HIF-1a was indeed made possible
by targeting EPO itself as downstream protein regulated
by hypoxia (Semenza et al., 1991). Today, however,
HIF-2a, also known as EPAS-1 (endothelial PAS
domain protein 1), seems to be more critical than
HIF-1 in overexpressing EPO during hypoxia (Chavez
et al., 2006; Haase, 2013). Although the classical
hypoxia-dependent EPO/EPOR system was long believed
to target the kidney-erythroid axis, today, the brain axis
is highlighted as an important protective mechanism,
based on the observation that EPO and EPOR are
expressed in those regions of the brain that are most sen-
sitive to hypoxia, that is, the hippocampus and the telen-
cephalon (Digicaylioglu et al., 1995). Thus, it is tentative
to speculate that EPO’s physiological role in the brain is
to act as a protective agent against hypoxia (Rabie and
Marti, 2008) and, possibly, ischemia. To this end, the role
of EPO in brain ischemia has been widely studied and
will be discussed in depth in a subsequent section. Even
so, it is worth noting that ischemia-preconditioned
neurons protect neighboring astrocytes through an
EPO-mediated activation of antioxidant proteins and
enzymes (Wu et al., 2017). ROS also have a role in per-
petrating tissue damage and neuronal death in numerous
other neurodegenerative disorders (Kim et al., 2015; Liu
et al., 2017b). More specifically, EPO antioxidant mech-
anisms reduce beta-amyloid-induced cell death (Li et al.,
2008) and increases tyrosine hydroxylase (TH)-positive
neurons in a rat model of Parkinson’s disease (PD;
Erbas¸ et al., 2015).
If EPO and HIF-1 respond to hypoxia, it is tempting
to believe that excess oxygen, or hyperoxia, has opposite
outcomes. Despite being a straightforward paradigm, lit-
erature is, however, very controversial. Although a few
early studies support this view (Fletcher et al., 1973;
Kokot et al., 1994a, 1994b), more recent studies testing
the effects of transient hyperoxia on EPO blood levels
show increased, not decreased, circulating EPO
(Balestra et al., 2006, 2004; Donati et al., 2017; Kiboub
et al., 2018). This has also been confirmed in a clinical
trial (Hyperoxia, Erythropoiesis and Microcirculation in
Critically Ill Patient, NCT02481843). Still another study
shows a significant increase of EPO production after a
short-term hyperoxic stimulus, only when preceded by
antioxidants administration (Momeni et al., 2011;
Rocco et al., 2014). This apparently paradoxical response
has a strong mechanistic background. Indeed, despite
their name, HIFs are stabilized not only by hypoxia
but also by hyperoxia. This feature was observed in
rats’ brains exposed to 50% oxygen for 3 weeks
Figure 2. Neurotrophic role of EPO’s binding with EPOR. In the
CNS, EPO’s binding to its receptor leads to an increase in neuro-
protective actions (synaptic plasticity, neurogenesis, autophagy)
with an overall functional recovery in animal models. Conversely,
the binding leads to a decrease in apoptosis, expression of miRNAs
regulating the apoptotic process, oxidative stress, and neuroin-
flammation. Made in !BioRender—biorender.com
EPO¼ erythropoietin; EPOR¼ erythropoietin receptor.
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(Benderro et al., 2012) as well as in mice exposed to 30%
oxygen (Terraneo et al., 2017). These key findings are
indirectly confirmed in growing prostate cancer
(Terraneo et al., 2014), myocardium (Wikenheiser
et al., 2009; Zara et al., 2012; Gyongyosi et al., 2018)
as well as newborn rats hepatocytes and liver hemopoi-
etic cells (Marconi et al., 2014). It has been pointed out
that the main reason for the high sensitivity of HIF’s to
hyperoxia may not be related to HIF mRNA but rather
to a decreased expression of the prolyl hydroxylases that
degrade and address HIF’s toward ubiquitination
(Terraneo and Samaja, 2017). The generation of oxida-
tive stress in both hypoxia and hyperoxia may play an
additional pivotal role in HIF stabilization and hence
EPO production. Although ROS blockade is clearly asso-
ciated with increased prolyl hydroxylation and therefore
decreased HIF activity (Chandel et al., 2000; Brunelle
et al., 2005; Guzy et al., 2005; Kaelin, 2005), it is not
clear in which direction lack or excess oxygen modulates
the oxidative stress in the brain. For example, long-term
30% oxygen cause less oxidative stress than 10% oxygen
(Terraneo et al., 2017). Nevertheless, the recent finding of
a molecular mechanisms for HIF-1a activation alterna-
tive of hydroxylation, which depends on the cAMP-PKA
pathway, could provide an explanation for this apparent-
ly contradictory behavior (Bullen et al., 2016). The mech-
anism through which EPO/EPOR interaction modulates
oxidative stress has been summarized in Figure 3.
EPO’s Function in Suppressing Neuroinflammation
EPO has emerged as a multifunctional tissue-protective
cytokine, and this is partially due to its anti-
inflammatory effects (Wang et al., 2011; Sanchis-
Gomar et al., 2014). Indeed, when rhEPO is administered
in the setting of focal brain ischemia in rats, it crosses the
blood–brain barrier and reduces injury severity by 50%
to 75% (Brines et al., 2000). rhEPO appears effective in
preclinical models of other types of injury in the nervous
system whose gravity is exacerbated by inflammation
(Sugawa et al., 2002). In a preclinical model of multiple
sclerosis (consisting in experimental autoimmune
Figure 3. Role of the EPO/EPOR pathway in opposing the oxidative stress induced by hypoxia or hyperoxia. Both hypoxia and hyperoxia
are sources of oxidative stress and activate the HIF pathway, which leads to increased EPO expression and EPO/EPOR interaction, which
activates the antiapoptotic STAT3 pathway, and increases the antioxidant enzymes expression through the Nrf1 pathway. Green arrows:
activation. Red lines: inhibition. Made in !BioRender—biorender.com
EPO¼ erythropoietin; EPOR¼ erythropoietin receptor; HIF-1¼ hypoxia-inducible factor 1; IL-6¼ interleukin-6; IL-8¼ interleukin-8;
Nrf1¼ nuclear respiratory factor 1; TNF-a¼ tumor necrosis factor alpha; ROS¼ reactive oxygen species; STAT3¼ signal transducer and
activator of transcription 3.
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encephalitis), rhEPO reduced the production and release
of proinflammatory cytokines and chemokines, and the
influx of inflammatory cells into the injured tissue
(Agnello et al., 2002). EPO’s neuroprotective effect is
mediated by EPOR; this is particularly relevant during
hypoxia, where it has been proposed to contribute to
endogenous neuroprotection during carotid endarterec-
tomy (Fantacci et al., 2006; Carelli et al., 2016a;
Terraneo et al., 2017; Terraneo and Samaja, 2017). The
mechanism whereby EPO exerts its neuroprotective
action might involve activation of the antiapoptotic
STAT3 pathway (Ponce et al., 2013; Jia et al., 2014),
the increase of antioxidant enzymes expression, and the
reduction of ROS production (Bartesaghi et al., 2005;
Chavez et al., 2006).
Novel Potential Targets: Modulation of RNA Expression
In recent years, the role of the noncoding epigenome in
disease mechanisms is gaining more and more impor-
tance. Among the multiple mechanisms implicated in
neurodegeneration, a new attention has been posed on
the alteration of RNA processing and function in neu-
rodegenerative diseases (Liu et al., 2017a). New studies
have implicated more and more different classes of non-
coding RNAs (ranging from microRNAs to long non-
coding RNAs) in neurodegeneration (Salta and De
Strooper, 2017). An epigenetic activity for EPO has
been reported for erythroid cells proliferation
(Perreault et al., 2017), but a similar regulation in the
brain is yet to be fully characterized. Interestingly, EPO
downregulates two microRNA molecules (miR-451 and
miR-855-5p) in the SH-SY5Y neuroblastoma cell line
(Alural et al., 2014). This downregulation seems to be
responsible for the neurotrophic, neuroprotective, anti-
oxidant, and antiapoptotic effects observed after EPO’s
administration in SH-SY5Y (Alural et al., 2014). EPO’s
downregulation of miR-451 also has a possible implica-
tion in the progression of glioblastoma (Alural et al.,
2017). Further studies by transcriptomic approach
investigated the deregulated RNAs which could be asso-
ciated with EPOR’s signaling (Sollinger et al., 2017).
Indeed, EPOR deletion in rodent fetal NPCs is associ-
ated with altered expression of key transcriptional and
epigenetic regulators in the developing CNS. Multiple
transcriptomic analysis revealed different factors
involved, such as REST and NRF1. REST is an epige-
netic modifier involved in neural differentiation and
plasticity (Gao et al., 2011). NRF1 is a key regulator
of antioxidant response and mitochondrial biogenesis
(Lee et al., 2011). These two factors could act mediating
EPO’s downstream pathway in the developing CNS
(Sollinger et al., 2017).
EPO’s Implications in
Neurodegenerative Diseases
To this day, there is no curative therapy for the treatment
of neurodegenerative diseases. Along with the canonical
first line therapies used for each specific neurodegenera-
tive disease, new therapies are now being investigated.
Epigenetic therapy, gene therapy, stem cells therapy,
and even 3-D organoids are gaining more and more rel-
evance in this context (Sakthiswary and Raymond, 2012;
Coppede`, 2014; Piguet et al., 2017; Bordoni et al., 2018).
Even so, the potentiality of a single-drug therapy is not to
be underestimated, and EPO’s role as a therapeutic agent
in neurodegenerative diseases is clearly worth investigat-
ing (Brines and Cerami, 2005).
Parkinson’s Disease
PD is the second most common neurodegenerative disor-
der. Its symptoms can be both motor (bradykinesia,
rigidity, and tremor) and nonmotor (these can precede
the manifestation of the disease; Tysnes and Storstein,
2017). The two main pathological hallmarks are the
death of dopaminergic neurons in the substantia nigra
pars compacta (Wirdefeldt et al., 2011) and the presence
of alpha synuclein aggregates, noted as primary compo-
nents of Lewy bodies (Benskey et al., 2016). These aggre-
gates lead to cellular toxicity with an increase in oxidative
stress and neuroinflammation (Benskey et al., 2016).
Dopaminergic agonists (such as L-3,4-dihydroxypheny-
lalanine, L-DOPA) are the first line of therapy for PD
treatment, but they are only a symptomatic remedy as
they do not provide permanent or disease-altering effects
(Nutt and Wooten, 2005). Various studies have reported
EPO’s ability to counteract numerous processes altered
in PD, such as oxidative stress, inflammation, and
mitochondrial dysfunction (Jang et al., 2016).
Neuroprotective effects have been demonstrated in
numerous in vitro and in vivo PD models. Examples
include improvements in the vitality and an alteration
of the Bax/Bcl-2 ratio in PC12 cells intoxicated with
1-methyl-4-phenylpyridinium (Wu et al., 2007). EPO
treatment induces the autophagy process in rotenone-
treated SH-SY5Y cells, as observed with a specific anal-
ysis of autophagy markers, such as Beclin-1, AMPK, and
ULK-1 (Jang et al., 2016). Another possible pathway in
which EPO could be involved is the activation of PI3K/
Akt/FoxO3a signaling, known to be able to prevent apo-
ptosis (Maiese et al., 2012). It has been shown that PC12
cells pretreated with 6-hydroxydopamine show a major
vitality after EPO’s administration (Jia et al., 2014).
EPO is involved in neuroinflammation modulation
with different neurotrophic actions on astrocytes, micro-
glia, and neurons (Bond and Rex, 2014). Indeed, EPO is
able to preserve the blood–brain barrier through the
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inhibition of microvascular endothelial cells’ apoptosis
and astrocytes’ activation (Maiese et al., 2012).
Specifically, astrocytes respond to EPO’s presence
through the activation of JNK and p38-MAPK, a
decrease of glial swelling, and a reduction of blood–
brain barrier permeability (Gunnarson et al., 2009;
Tang et al., 2013). It has also been shown that the upre-
gulation of the stress-induced intermediate filament pro-
tein is associated with glial hypertrophy, and it is
decreased by EPO, independently of the MAPK pathway
(Gonzalez et al., 2013). Moreover, EPO may directly
influence the reactive microglia, which has the ability to
engulf dying neurons through the increased expression of
phosphatidylserine receptor, which specifically targets
apoptotic neurons (De et al., 2002; Bond and Rex,
2014). EPO decreases the in vitro levels of the phospha-
tidylserine receptor on the microglial plasma membrane,
suggesting its ability to redirect microglia and prevent its
proliferation (Chong et al., 2003). Interestingly, EPO’s
specific action on neurons is still widely unknown, but
the presence of EPOR’s receptor indicates a specific func-
tion for the molecule in this context (Constantinescu
et al., 1999; Brines and Cerami, 2005, 2012). Moreover,
EPO has been found to block apoptosis in retinal neu-
rons (Grimm et al., 2002; Weishaupt et al., 2004; Bond
and Rex, 2014).
Different signaling effects of EPO as a neuroprotective
molecule have been tested in vivo, specifically in rodent
models of PD. It has been reported that EPO restores the
levels of TH in rats in which parkinsonism has been
induced with rotenone or 6-hydroxydopamine and
decreases the levels of tumor necrosis factor alpha, indi-
cating that EPO could exert its mechanisms through the
modulation of neuroinflammation (Qi et al., 2014; Erbas¸
et al., 2015). The importance of EPO’s paracrine release
has been investigated, with particular reference to the
neuroprotective effects of a class of NPCs able to release
erythropoietin (Er-NPCs) in a murine model of PD
(Marfia et al., 2011; Carelli et al., 2016b, 2017b). The
injection of Er-NPCs in mice, pretreated with 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine, promotes functional
recovery and enhances survival of nigrostriatal neurons
associated to the restored levels of TH. These effects are
likely due to a modulation of the neuroinflammatory
process, as Er-NPCs are able to reduce the expression
of early proinflammatory and microglia markers
(Carelli et al., 2018). To this day, only two clinical
trials have studied the role of rhEPO in PD patients
(Pedroso et al., 2012; Jang et al., 2014). Pedroso et al.
(2012) demonstrated the safety of ior-EPOCIM, a recom-
binant human EPO produced in Cuba and approved for
use in humans, in 10 PD patients (Pedroso et al., 2012).
They evaluated its possible neuroprotective effects and
demonstrated improvements in motor functions, cogni-
tive status, and mood. To investigate any possible side
effect linked to the hematopoietic action of EPO, haema-
tological parameters and blood pressure were evaluated,
noting no adverse reactions (Pedroso et al., 2012). The
second clinical trial showed that rhEPO has positive
effects on nonmotor symptoms in PD patients, such as
pain, apathy, and sexual difficulty. Again, no side effects
due to hypertension or iron deficiency were observed, and
this was true for the whole 12 months observational
period (Jang et al., 2014).
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of
dementia, clinically characterized by a progressive loss of
memory and a decline in cognitive functions (Karch
et al., 2014). The first evidences indicating that EPO
could have a role in improving cognitive functions
arose from observations relating to nonneurological dis-
eases, where patients in hemodialysis treated with EPO
demonstrated an improvement in cognitive functions
(Grimm et al., 1990; Temple et al., 1995). These early
observations led to more in-depth studies aiming to char-
acterize the pleiotropic effects of the molecule and its
potential benefits in diseases where cognitive function
was impaired, such as AD (Rabie and Marti, 2008;
Herna´ndez et al., 2017). At a cellular level, the hallmarks
of the disease are the presence of extracellular neuritic
plaques (due to Ab aggregation) and intracellular neuro-
fibrillary tangles (characterized by a hyperphosphoryla-
tion of the tau protein; Blennow et al., 2006). So far, no
curative treatment has been found for AD, and classic
pharmacological therapy includes acetylcholinesterase
inhibitors, N-methyl-D-aspartate antagonists, and their
possible combination (Madav et al., 2019). For this
reason, it is necessary to evaluate the therapeutic poten-
tials of new approaches and molecules, such as EPO.
Indeed, multiple studies have already been performed,
showing promising results (Sun et al., 2019). The thera-
peutic effects of EPO have been first studied at a cellular
level, using both stable cell lines, such as PC12 (Li et al.,
2008), and primary hippocampal neurons (Viviani et al.,
2005). The molecule seems to exert its effect through the
blockade of the apoptotic pathway and the protection
from Ab toxicity (Ma et al., 2009; Esmaeili Tazangi
et al., 2015). Moreover, it is possible to observe a
taming of the neuroinflammatory response (Shang
et al., 2011, 2012) and an increase of antioxidant mech-
anisms (Li et al., 2008). Interestingly, EPO also shows a
neurotrophic function in primary hippocampal neurons
through the expression of BDNF (Viviani et al., 2005).
Most of these neuroprotective effects observed in vitro
have been evaluated in vivo in preclinical models of the
disease. First of all, EPO injections reduced the levels of
Ab in transgenic and Ab treated mice and rats (Lee et al.,
2012; Shang et al., 2012; Armand-Ugon et al., 2015;
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Samy et al., 2016; Rodrıguez Cruz et al., 2017), demon-
strating the molecule’s ability in tackling the first patho-
logical hallmark of the disease. Furthermore, EPO
seemed to decrease tau hyperphosphorylation (Li et al.,
2015), reduce neuroinflammation and oxidative stress
(Shang et al., 2012; Maurice et al., 2013), and increase
neurogenesis (Arabpoor et al., 2012). Preclinical murine
models have become crucial for the assessment of behav-
ioral functions. Indeed, EPO treatment improved cogni-
tive results in AD mice models, when learning and spatial
memory were evaluated. Both in transgenic and Ab
treated mice models, EPO’s administration led to
improvements in fear-conditioning and step-down avoid-
ance tests, where the treated animals showed a recovery
of associative learning memory (Lee et al., 2012; Li et al.,
2015). AD animals performed better in tests aimed at
evaluating spatial memory (Morris Water Maze and
Y-maze) when treated with EPO, indicating effects for
the molecule in this type of learning (Maurice et al.,
2013; Rodrıguez Cruz et al., 2017). Furthermore, the
molecule seems to have a recovery effect on synaptic
plasticity defects (Adamcio et al., 2008; Esmaeili
Tazangi et al., 2015). This, together with the fact that
EPOR is expressed in the hippocampus (Lee et al.,
2012), suggests the possibility for elective effects of
EPO in this disease (Herna´ndez et al., 2017). Although
no clinical trials involving EPO have been performed so
far in AD, one study investigated the effect of rhEPO on
the amyloidogenic pathway proteins in patients affected
by chronic kidney disease associated with cognitive dys-
function. Even if the patients enrolled in this study were
young (age range 20–39), the platelets level of
AD-associated proteins was altered: The amyloid precur-
sor protein and a secretase decreased, and BACE1, pre-
senilin 1, and Ab increased. Western blot analysis
revealed that these protein abnormalities could be
reverted by rhEPO treatment, along with improved neu-
ropsychological tests scoring (Vinothkumar et al., 2018),
thereby suggesting promise for EPO in AD treatment.
Furthermore, in a clinical report of an AD patient with
trochanteric fracture of the left femur and chronic renal
failure associated with severe anemia, rhEPO treatment
increased the speech level after 2 days and the food intake
after 8 days, which substantially improved the patient’s
quality of life (Kumagai et al., 2018). These authors state
that the daily living activities could improve due to the
EPO antidepressant effects that preceded the correction
of anemia (Kumagai et al., 2018).
Amyotrophic Lateral Sclerosis
Out of all the motor neuron diseases, amyotrophic lateral
sclerosis (ALS) is the most prevalent. It is characterized
by the progressive loss of upper and lower motor neu-
rons, leading to muscle atrophy, paralysis, and death 2 to
5 years after the first diagnosis (Wijesekera and Leigh,
2009). Perhaps the most tragic effect of ALS, which even-
tually leads to patients’ death, is the respiratory muscle
weakness, which causes ventilator insufficiency and tissue
hypoxia (Carilho et al., 2011). This observation led to the
investigation of the role of EPO in ALS. Initial studies
focused on the expression levels of EPO in cerebrospinal
fluid, serum, and plasma of ALS patients. Studies dem-
onstrated a decrease of EPO levels in ALS patients’ cere-
brospinal fluid but not in patients’ serum (Brettschneider
et al., 2007; Widl et al., 2007). Further studies indicated
that EPO levels were decreased in the plasma of only a
subset of ALS patients, which are those that presented
with respiratory failure (Carilho et al., 2011). In vitro
study aimed to elucidate how EPO could exert its protec-
tive actions in ALS patients and demonstrated that EPO
prevented apoptotic neuronal changes and could even
decrease the levels of the superoxide dismutase (SOD1)
aggregates (Naganska et al., 2010; Cho et al., 2011). The
preclinical investigation of the beneficial effects of EPO
was performed in SOD1-G93A mice, a model of familial
ALS (Grignaschi et al., 2007). The results obtained in
these studies, all performed in SOD1-G93A mice, are
controversial. Indeed, two of them indicated that EPO
delays only symptoms onset with not beneficial effects on
mice survival (Grignaschi et al., 2007; Grunfeld et al.,
2007). On the contrary, other studies indicated that
EPO treatment significantly delayed symptom onset, pro-
longed life span, preserved motor neurons, and modulat-
ed the immune-inflammatory response (Koh et al., 2007;
Noh et al., 2014). Even so, two different clinical trials
aiming at studying rhEPO’s effects in ALS patients
were started. Both studies demonstrated that treatment
was safe and well tolerated, with no increase in the levels
of haematocrit and haemoglobin (Lauria et al., 2009;
Kim et al., 2014). The Phase III of the study performed
by Lauria et al. (2009) indicated that no differences were
observed in the rate of death or secondary outcomes in
patients treated with EPO, suggesting that different doses
of the molecule or a more target specific administration
could be necessary (Lauria et al., 2015).
Spinal Cord Injury
Spinal cord injury (SCI) is a debilitating condition caused
by high-energy trauma. It is characterized by severe neu-
rological dysfunctions ranging from sensation loss to
partial or complete limb paralysis (Profyris et al.,
2004). The trauma leads to the release of toxic substances
such as free radicals, lipid peroxidase, eicosanoids, and
glutamate, causing neuronal and glial apoptosis (Hock,
1998; Profyris et al., 2004; Mofidi et al., 2011). The main
strategy to promote recovery following SCI is the reduc-
tion of secondary degeneration occurring after the initial
injury. There is now no curative therapy, and the current
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main therapeutic strategy is the reduction of secondary
degeneration through the administration of high-dose
corticosteroids, surgical stabilization, and decompression
(King et al., 2007; Furlan et al., 2011). Various pharma-
cological agents are currently being evaluated in humans
and animals, aimed at reducing SCI consequences, and
EPO is resulting to be a very promising candidate (Celik
et al., 2002; Leist et al., 2004; Gorio et al., 2005; Cetin
et al., 2006; Carelli et al., 2014, 2015, 2017a). The bene-
ficial neuroprotective and neurotrophic effects have been
demonstrated in vitro and in vivo, where EPO’s adminis-
tration led to a partial recovery of motor function (Rees
et al., 2010; Mofidi et al., 2011; Cerri et al., 2012). EPO
seemed to exert its beneficial effects through the preven-
tion of secondary injury and neurodegeneration, proba-
bly through the combination of anti-inflammatory and
neuroprotective actions (Gorio et al., 2002, 2005;
Simon et al., 2011; Gre´goire et al., 2015). Indeed, EPO
led to antiapoptotic and anti-inflammatory effects, along
with edema reduction (Simon et al., 2011, 2016; Nekoui
and Blaise, 2017; Zhang et al., 2018).
Stem cells and stem cell-derived molecules have shown
beneficial effects to a variable extent in the treatment of
SCI (Martino and Pluchino, 2006; Romanko et al., 2007).
Er-NPCs also show a beneficial effect when applied to
SCI, leading to a promotion of axonal regeneration and
an increase in TH-positive fibers in the ventral portion of
the lumbosacral cord of the treated mice (Carelli et al.,
2014, 2015, 2017a). Furthermore, Er-NPCs modify the
microenvironment reducing the production of proinflam-
matory cytokines, such as tumor necrosis factor alpha and
IL-6, and the infiltration of inflammatory cells (Carelli
et al., 2014, 2015, 2017a). EPO also induces neurogenesis
increasing BDNF’s activity (Mofidi et al., 2011; Carelli
et al., 2015). To this day, only one clinical trial has been
designed to study the role of rhEPO in SCI (Costa et al.,
2015) in which it has been shown that the administration
of rhEPO in acute SCI is safe. Unfortunately, the limited
number of patients recruited and the short observational
period were not sufficient to demonstrate EPO’s efficacy
(Costa et al., 2015).
Brain Ischemia
Ischemic stroke is due to transient or permanent reduction
in cerebral blood flow, generally caused by the occlusion
of a cerebral artery, an embolus, or local thrombosis,
which cause acute ischemia stroke (AIS; Dirnagl et al.,
1999). The most common consequence of AIS is hypoxia,
or the imbalance between oxygen supply and consump-
tion (Dirnagl et al., 1999). Activation ofHIF’s upregulates
downstream factors, such as the vascular endothelial
growth factor and EPO, which exert a neuroprotective
action against ischemic damage (Dirnagl et al., 1999).
Further consequences of ischemic strokes are the increase
in ROS, as well as the inflammatory response by means of
induction of proinflammatory genes, as tumor necrosis
factor alpha and interleukin 1 beta (Ruscher et al.,
1998). In in vitro models of hypoxia, EPO’s expression is
upregulated in both murine astrocytes and neurons
(Suzuki et al., 2001). It seems that EPO acts on forebrain
neural stem cells, suggesting its involvement in neurogen-
esis (Dirnagl et al., 1999). In primary hippocampal and
cortical neurons subjected to cerebral ischemia, cell viabil-
ity improves following EPO treatment, suggesting its
involvement in apoptosis and cell recovery (Dirnagl
et al., 1999; Marti, 2004). Another study confirms EPO’s
role in apoptosis: EPO pretreatment in cerebral cortical
cells indeed activates antiapoptotic genes, such as XIAP
and c-IAP2 (Ruscher et al., 1998; Suzuki et al., 2001).
Several experimental works demonstrated the involve-
ment of the EPO/EPOR system in neuroprotection
(Rothwell and Hopkins, 1995). rhEPO administration
prevented ischemia-induced learning disability by rescu-
ing hippocampal CA1 neurons from lethal ischemic
damage (Lewczuk et al., 2000), while another study
showed that the endogenous EPO/EPOR system helps
protecting hypoxic astrocytes and oligodendrocyte pre-
cursor cells, showing that the suppression of endogenous
EPO in astrocytes implies decreased protection of oligo-
dendrocyte precursor cells and cell death (Bernaudin
et al., 2000). This hypothesis is further supported by
the fact that in the mammalian brain exposed to ischemic
infarct or hypoxic damage, the EPO/EPOR system
results activated and EPOR is expressed in neuronal
fibers (Shingo et al., 2001). Other studies demonstrate
that even though EPOR transcription is not directly
influenced by hypoxia in vivo, anemic stress and ischemic
conditions enhance its expression (Lewczuk et al., 2000;
Digicaylioglu and Lipton, 2001). Another work on in vivo
rabbits demonstrate that rhEPO is neuroprotective
during cerebral AIS, showing a significant reduction of
necrotic cortical neurons (Sanchez et al., 2009).
Furthermore, rhEPO reduces the activation of astrocytes
and the recruitment of leukocytes and of proinflamma-
tory cytokines as IL-6 and tumor necrosis factor, suggest-
ing that EPO can help reducing ischemia-induced
inflammation (Sakanaka et al., 1998).
A few clinical trials tested the potential effects of EPO
in AIS patients. The safety of rhEPO was demonstrated,
showing that rhEPO, when infused intravenously 3 days
after stroke, can pass the blood–brain barrier reducing
the infarct size (Ehrenreich et al., 2002). Another study
tested EPO’s effects on long-term neurological outcomes
in AIS patients and evaluated EPO’s safety and benefits
(Tsai et al., 2015). By contrast, a meta-analysis support-
ing the view that the efficacy evidence is inconsistent
indicates that EPO’s administration in AIS patients is
not recommended (Yao et al., 2017). It is thus evident
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that more studies are needed to assess rhEPO efficacy in
AIS patients.
Brain Hypoxia and Hyperoxia
The discovery that HIF-1a binds to the EPO enhancer
sequence in response to hypoxia (Semenza and Wang,
1992) univocally addresses the key role of EPO/EPOR
to protect the neurological functions in brain tissue chal-
lenged not only by hypoxia (Sanchez et al., 2009;
Terraneo et al., 2017), but also by ischemia (Sakanaka
et al., 1998), carotid clamping (Carelli et al., 2016a), and
hypoxia/reoxygenation (Kato et al., 2011). The most rel-
evant mechanisms underlying neuroprotection involve
Table 1. Summary of the Studies Describing EPO’s Neurotrophic Effect in Neurodegenerative Diseases.
Pathology Description References
Parkinson’s disease
In vitro EPO increases cell viability altering the Bax/Bcl-2 ratio in PC12
cells intoxicated with MPPþ, modulates the autophagy process
in rotenone-treated SH-SY5Y cells, activates the PI3K/Akt/
FoxO3a pathway, and modulates neuroinflammation.
Wu et al., 2007; Maiese et al., 2012; Bond
and Rex, 2014; Jia et al., 2014; Jang
et al., 2016
In vivo EPO restores TH levels and reduces the expression of early
proinflammatory cytokines and microglia markers.
Qi et al., 2014; Erbas et al., 2015; Carelli
et al., 2016a, 2017b, 2018
Clinical trials EPO has positive effects on nonmotor symptoms, such as pain,
apathy, and sexual difficulty.
Pedroso et al., 2012; Jang et al., 2014
Alzheimer’s disease
In vitro EPO is used to block the apoptotic pathway and protects from Ab
toxicity, increases antioxidant mechanisms, and has a neuro-
trophic function in primary hippocampal neuron through
BDNF’s expression.
Viviani et al., 2005; Li et al., 2008; Ma et al.,
2009; Shang et al., 2011, 2012; Esmaeili
Tazangi et al., 2015
In vivo EPO decreases tau hyper phosphorylation, reduces neuroinflam-
mation and oxidative stress, increases neurogenesis, improves
cognitive results in AD mice models, and improves synaptic
plasticity but no effect on anxiety and spontaneous activity.
Lee et al., 2012; Armand-Ugon et al., 2015;
Li et al., 2015; Samy et al., 2016;
Herna´ndez et al., 2017; Rodrıguez Cruz
et al., 2017
Clinical trials EPO improves neuropsychological test scoring in chronic kidney
disease and ameliorates AD patient’s daily living.
Kumagai et al., 2018; Vinothkumar
et al., 2018
Amyotrophic lateral sclerosis
In vitro EPO prevents apoptotic neuronal changes and decreases the levels
of the SOD1 aggregates.
Naganska et al., 2010; Cho et al., 2011
In vivo EPO administration delays symptoms, preserves motor symp-
toms, and modulates the neuroinflammatory response, but
results are controversial with regard to the life span.
Grignaschi et al., 2007; Grunfeld et al.,
2007; Koh et al., 2007; Noh et al., 2014
Clinical trials EPO administration has no adverse effects Lauria et al., 2009; Kim et al., 2014
Spinal cord injury
In vivo EPO administration leads to a partial recovery of motor function,
prevents the secondary injury through anti-inflammatory and
neuroprotective actions, increases TH-positive fibers of lum-
bosacral cord of treated mice, reduces the production of
proinflammatory cytokines, and induces neurogenesis increasing
BDNF activity.
Gorio et al., 2002, 2005; Rees et al., 2010;
Mofidi et al., 2011; Simon et al., 2011;
Cerri et al., 2012; Carelli et al., 2014,
2015, 2017b
Clinical trials EPO’s effect was not efficiently evaluated. Costa et al., 2015
Brain ischemia
In vitro EPO acts on neurogenesis, is involved in apoptotic and cellular
recovery, and activates antiapoptotic genes.
Ruscher et al., 1998; Dirnagl et al., 1999;
Suzuki et al., 2001; Marti, 2004
In vivo EPO administration is involved in neuroprotection. Shingo et al., 2001; Sanchez et al., 2009
Clinical trials EPO reduces infarct size. Tsai et al., 2015; Yao et al., 2017
Brain hypoxia and hyperoxia
In vivo EPO ameliorates the metabolic stress and induces neuroprotec-
tion in chronic hypoxia.
Chung et al., 2015; Fantacci et al., 2006
Clinical trials EPO treatment in newborns with hypoxic-ischemic encephalopa-
thy improves neurological outcomes.
Zhu et al., 2009
Note. EPO¼ erythropoietin; MPPþ¼ 1-methyl-4-phenylpyridinium; PI3K¼ phosphatidylinositol 3-kinase; TH¼ tyrosine hydroxylase; BDNF¼ brain-derived
neurotrophic factor; AD¼Alzheimer’s disease; SOD1¼ superoxide dismutase.
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either the prevention of neuronal apoptosis through
upregulation of Akt phosphorylation (Chong et al.,
2002; Caretti et al., 2008) or the increase of vascular
NO availability through activation of eNOS (Beleslin-
Cokic et al., 2004). In support of these mechanisms,
treatment with rhEPO may provide clues for EPO-
based therapy in pediatric chronic hypoxia by rescuing
hypoxia-induced depression in hippocampal neurogene-
sis and oligodendrocyte progenitor populations (Chung
et al., 2015), as well as in improving neurologic outcomes
in newborns affected with hypoxic-ischemic encephalop-
athy (Zhu et al., 2009). To prevent erythropoiesis, carba-
mylated EPO, a derivative devoid of erythropoietic
activity, represents a solid pharmacological tool to pro-
tect brain in severely hypoxic mice (Fantacci et al., 2006).
As stated earlier, hyperoxia may represent a valuable
bench to test the hypothesis linked to the endogenous
hypoxia-induced, EPO-mediated neuroprotection. The
effect of experimental hyperoxia on brain EPO overex-
pression was examined in two studies with controversial
outcomes. While breathing 50% oxygen for 3 weeks
upregulates HIF-2a and EPO expressions in mouse
brain (Benderro et al., 2012), breathing 30% oxygen for
4 week increases EPOR, but not EPO expression
(Terraneo et al., 2017). As the EPO/EPOR system of
neuroprotection requires the availability of both EPO
and EPOR, it remains to be understood whether the
recruitment of this system depends only on oxygen avail-
ability or other components are to be ruled in.
Future Challenges
A critical attention needs to be put to avoid the risk of
adverse reactions, which would involve the hematopoiet-
ic system when EPO is chronically administered. To this
end, EPO analogues are currently being investigated (Sun
et al., 2019). These can present reduced erythropoietic
activity or be posttranscriptionally modified to yield a
molecule with enhanced clearance or selectively target
the EPOR receptor (King et al., 2007; Armand-Ugon
et al., 2015; Collino et al., 2015; Culver et al., 2017;
Yoo et al., 2017). The development of novel EPO ana-
logues with a more specific action and fewer side effects
necessarily requires deeper investigation to decipher the
relationship between the different isoforms of the recep-
tor and the different functions of EPO.
Conclusions
Considering all the advances made in the recent years,
EPO has shown great promise in the treatment of neuro-
degenerative diseases. It is able to target multiple path-
ways, which are deregulated in neurodegeneration,
leading to an overall neuroprotective effect (Table 1).
Summary
EPO is a cytokine with a broad action on the CNS, where
it is able to target multiple pathways that are deregulated
in neurodegenerative diseases, leading to an overall neu-
roprotective effect.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with
respect to the research, authorship, and/or publication of
this article.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: The authors acknowledge the economic support of the
“Neurogel-en-Marche” Foundation (France), AUS Niguarda
Onlus (Italy) to S.C., and Fondazione “Romeo and Enrica
Invernizzi” to A. M. D. G.
ORCID iD
Stephana Carelli https://orcid.org/0000-0003-4603-396X
References
Adamcio, B., Sargin, D., Stradomska, A., Medrihan, L.,
Gertler, C., Theis, F., Zhang, M., Mu¨ller, M., Hassouna,
I., Hannke, K., Sperling, S., Radyushkin, K., El-Kordi,
A., Schulze, L., Ronnenberg, A., Wolf, F., Brose, N.,
Rhee, J. S., Zhang, W., & Ehrenreich, H. (2008).
Erythropoietin enhances hippocampal long-term potentia-
tion and memory. BMC Biol, 6, 37.
Agnello, D., Bigini, P., Villa, P., Mennini, T., Cerami, A.,
Brines, M. L., & Ghezzi, P. (2002). Erythropoietin exerts
an anti-inflammatory effect on the CNS in a model of exper-
imental autoimmune encephalomyelitis. Brain Res
952, 128–134.
Alural, B., Ayyildiz, Z. O., Tufekci, K. U., Genc, S., & Genc,
K. (2017). Erythropoietin promotes glioblastoma via miR-
451 suppression. Vitam Horm, 105, 249–271.
Alural, B., Duran, G. A., Tufekci, K. U., Allmer, J., Onkal, Z.,
Tunali, D., Genc, K., & Genc, S. (2014). EPO mediates
neurotrophic, neuroprotective, anti-oxidant, and anti-
apoptotic effects via downregulation of miR-451 and miR-
885-5p in SH-SY5Y neuron-like cells. Front Immunol, 5, 475.
Anagnostou, A., Lee, E. S., Kessimian, N., Levinson, R., &
Steiner, M. (1990). Erythropoietin has a mitogenic and pos-
itive chemotactic effect on endothelial cells. Proc Natl Acad
Sci U S A, 87, 5978–5982.
Arabpoor, Z., Hamidi, G., Rashidi, B., Shabrang, M., Alaei,
H., Sharifi, M. R., Salami, M., Dolatabadi, H. R., & Reisi,
P. (2012). Erythropoietin improves neuronal proliferation in
dentate gyrus of hippocampal formation in an animal model
of Alzheimer’s disease. Adv Biomed Res, 1, 50.
Arcasoy, M. O., Jiang, X., & Haroon, Z. A. (2003). Expression
of erythropoietin receptor splice variants in human cancer.
Biochem Biophys Res Commun, 307, 999–1007.
Rey et al. 11
Armand-Ugon, M., Aso, E., Moreno, J., Riera-Codina, M.,
Sa´nchez, A., Vegas, E., & Ferrer, I. (2015). Memory
improvement in the AbPP/PS1 mouse model of familial
Alzheimer’s disease induced by carbamylated-
erythropoietin is accompanied by modulation of synaptic
genes. J Alzheimers Dis, 45, 407–421.
Balestra, C., Germonpre, P., Poortmans, J. R., & Marroni, A.
(2006). Serum erythropoietin levels in healthy humans after
a short period of normobaric and hyperbaric oxygen breath-
ing: The “normobaric oxygen paradox”. J Appl Physiol,
100, 512–518.
Balestra, C., Germonpre, P., Poortmans, J., Marroni, A.,
Schiettecatte, J., Collard, J. F., & Snoeck, T. (2004).
Erythropoietin production can be enhanced by normobaric
oxygen breathing in healthy humans. Undersea Hyperb Med,
31, 53–57.
Bartesaghi, S., Marinovich, M., Corsini, E., Galli, C. L., &
Viviani, B. (2005). Erythropoietin: A novel neuroprotective
cytokine. Neurotoxicology, 26, 923–928.
Beleslin-Cokic, B. B., Cokic, V. P., Yu, X., Weksler, B. B.,
Schechter, A. N., & Noguchi, C. T. (2004). Erythropoietin
and hypoxia stimulate erythropoietin receptor and nitric
oxide production by endothelial cells. Blood,
104, 2073–2080.
Benderro, G. F., Sun, X., Kuang, Y., & Lamanna, J. C. (2012).
Decreased VEGF expression and microvascular density, but
increased HIF-1 and 2alpha accumulation and EPO expres-
sion in chronic moderate hyperoxia in the mouse brain.
Brain Res, 1471, 46–55.
Benskey, M. J., Perez, R. G., & Manfredsson, F. P. (2016).
The contribution of alpha synuclein to neuronal survival
and function – Implications for Parkinson’s disease.
J Neurochem, 137, 331–359.
Bernaudin, M., Bellail, A., Marti, H. H., Yvon, A., Vivien, D.,
Duchatelle, I., Mackenzie, E. T., & Petit, E. (2000). Neurons
and astrocytes express EPO mRNA: Oxygen-sensing mech-
anisms that involve the redox-state of the brain. Glia,
30, 271–278.
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006).
Alzheimer’s disease. Lancet, 368, 387–403.
Bond, W. S., & Rex, T. S. (2014). Evidence that erythropoietin
modulates neuroinflammation through differential action on
neurons, astrocytes, and microglia. Front Immunol, 5, 523.
Bordoni, M., Rey, F., Fantini, V., Pansarasa, O., Di Giulio,
A. M., Carelli, S., & Cereda, C. (2018). From neuronal dif-
ferentiation of iPSCs to 3D neuro-organoids: Modelling and
therapy of neurodegenerative diseases. Int J Mol Sci,
19, 3972–3985.
Brettschneider, J., Widl, K., Schattauer, D., Ludolph, A. C., &
Tumani, H. (2007). Cerebrospinal fluid erythropoietin
(EPO) in amyotrophic lateral sclerosis. Neurosci Lett,
416, 257–260.
Brines, M., & Cerami, A. (2005). Emerging biological roles for
erythropoietin in the nervous system. Nat Rev Neurosci,
6, 484–494.
Brines, M., & Cerami, A. (2012). The receptor that tames the
innate immune response. Mol Med, 18, 486–496.
Brines, M., Grasso, G., Fiordaliso, F., Sfacteria, A., Ghezzi, P.,
Fratelli, M., Latini, R., Xie, Q. W., Smart, J., Su-Rick, C. J.,
Pobre, E., Diaz, D., Gomez, D., Hand, C., Coleman, T., &
Cerami, A. (2004). Erythropoietin mediates tissue protection
through an erythropoietin and common beta-subunit heter-
oreceptor. Proc Natl Acad Sci U S A, 101, 14907–14912.
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de
Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A.
(2000). Erythropoietin crosses the blood-brain barrier to
protect against experimental brain injury. Proc Natl Acad
Sci U S A, 97, 10526–10531.
Brunelle, J. K., Bell, E. L., Quesada, N. M., Vercauteren, K.,
Tiranti, V., Zeviani, M., Scarpulla, R. C., & Chandel, N. S.
(2005). Oxygen sensing requires mitochondrial ROS but not
oxidative phosphorylation. Cell Metabol, 1, 409–414.
Bullen, J. W., Tchernyshyov, I., Holewinski, R. J., DeVine, L.,
Wu, F., Venkatraman, V., Kass, D. L., Cole, R. N., Van
Eyk, J., & Semenza, G. L. (2016). Protein kinase A-depen-
dent phosphorylation stimulates the transcriptional activity
of hypoxia-inducible factor 1. Sci Signal, 9, ra56.
Carelli, S., Ghilardi, G., Bianciardi, P., Latorre, E., Rubino, F.,
Bissi, M., Di Giulio, A. M., Samaja, M., & Gorio, A.
(2016a). Enhanced brain release of erythropoietin, cytokines
and NO during carotid clamping. Neurol Sci, 37, 243–252.
Carelli, S., Giallongo, T., Gerace, C., De Angelis, A., Basso,
M. D., Di Giulio, A. M., & Gorio, A. (2014). Neural stem
cell transplantation in experimental contusive model of
spinal cord injury. J Vis Exp, e52141.
Carelli, S., Giallongo, T., Gombalova, Z., Merli, D., Di Giulio,
A. M., & Gorio, A. (2017a). EPO-releasing neural precursor
cells promote axonal regeneration and recovery of function
in spinal cord traumatic injury. Restor Neurol Neurosci,
35, 583–599.
Carelli, S., Giallongo, T., Gombalova, Z., Rey, F., Gorio,
M. C. F., Mazza, M., & Di Giulio, A. M. (2018).
Counteracting neuroinflammation in experimental
Parkinson’s disease favors recovery of function: Effects of
Er-NPCs administration. J Neuroinflammation, 15, 333.
Carelli, S., Giallongo, T., Marfia, G., Merli, D., Ottobrini, L.,
Degrassi, A., Basso, M. D., Di Giulio, A. M., & Gorio, A.
(2015). Exogenous adult postmortem neural precursors
attenuate secondary degeneration and promote myelin spar-
ing and functional recovery following experimental spinal
cord injury. Cell Transplant, 24, 703–719.
Carelli, S., Giallongo, T., Viaggi, C., Gombalova, Z., Latorre,
E., Mazza, M., Vaglini, F., Di Giulio, A. M., & Gorio, A.
(2016b). Grafted neural precursors integrate into mouse stri-
atum, differentiate and promote recovery of function
through release of erythropoietin in MPTP-treated mice.
ASN Neuro, 8, 1–18.
Carelli, S., Giallongo, T., Viaggi, C., Latorre, E., Gombalova,
Z., Raspa, A., Mazza, M., Vaglini, F., Di Giulio, A. M., &
Gorio, A. (2017b). Recovery from experimental parkinson-
ism by intrastriatal application of erythropoietin or EPO-
releasing neural precursors. Neuropharmacology, 119, 76–90.
Caretti, A., Bianciardi, P., Ronchi, R., Fantacci, M., Guazzi,
M., & Samaja, M. (2008). Phosphodiesterase-5 inhibition
abolishes neuron apoptosis induced by chronic hypoxia
independently of hypoxia-inducible factor-1 alpha signaling.
Exp Biol Med, 233, 1222–1230.
12 ASN Neuro
Carilho, R., de Carvalho, M., Kuehl, U., Pinto, S., Pinto, A.,
Kromminga, A., & Costa, J. (2011). Erythropoietin and
amyotrophic lateral sclerosis: Plasma level determination.
Amyotroph Lateral Scler 12, 439–443.
Celik, M., G€okmen, N., Erbayraktar, S., Akhisaroglu, M.,
Konakc, S., Ulukus, C., Genc, S., Genc, K., Sagiroglu, E.,
Cerami, A., & Brines, M. (2002). Erythropoietin prevents
motor neuron apoptosis and neurologic disability in
experimental spinal cord ischemic injury. Proc Natl Acad
Sci U S A, 99, 2258–2263.
Cerri, G., Montagna, M., Madaschi, L., Merli, D., Borroni, P.,
Baldissera, F., & Gorio, A. (2012). Erythropoietin effect on
sensorimotor recovery after contusive spinal cord injury: An
electrophysiological study in rats. Neuroscience,
219, 290–301.
Cetin, A., Nas, K., Bu¨yu¨kbayram, H., Ceviz, A., & Olmez, G.
(2006). The effects of systemically administered methylpred-
nisolone and recombinant human erythropoietin after acute
spinal cord compressive injury in rats. Eur Spine J,
15, 1539–1544.
Chandel, N. S., McClintock, D. S., Feliciano, C. E., Wood,
T. M., Melendez, J. A., Rodriguez, A. M., & Schumacker,
P. T. (2000). Reactive oxygen species generated at mitochon-
drial complex III stabilize hypoxia-inducible factor-1alpha
during hypoxia: a mechanism of O2 sensing. J Biol Chem,
275, 25130–25138.
Chavez, J. C., Baranova, O., Lin, J., & Pichiule, P. (2006). The
transcriptional activator hypoxia inducible factor 2 (HIF-2/
EPAS-1) regulates the oxygen-dependent expression of
erythropoietin in cortical astrocytes. J Neurosci,
26, 9471–9481.
Cho, G. W., Kim, G. Y., Baek, S., Kim, H., Kim, T., Kim,
H. J., & Kim, S. H. (2011). Recombinant human erythro-
poietin reduces aggregation of mutant Cu/Zn-binding super-
oxide dismutase (SOD1) in NSC-34 cells. Neurosci Lett,
504, 107–111.
Chong, Z. Z., Kang, J. Q., & Maiese, K. (2002). Erythropoietin
is a novel vascular protectant through activation of Akt1
and mitochondrial modulation of cysteine proteases.
Circulation, 106, 2973–2979.
Chong, Z. Z., Kang, J. Q., & Maiese, K. (2003). Erythropoietin
fosters both intrinsic and extrinsic neuronal protection
through modulation of microglia, Akt1, Bad, and caspase-
mediated pathways. Br J Pharmacol, 138, 1107–1118.
Chong, Z. Z., Shang, Y. C., Mu, Y., Cui, S., Yao, Q., & Maiese,
K. (2013). Targeting erythropoietin for chronic neurodegen-
erative diseases. Expert Opin Ther Targets, 17, 707–720.
Chung, E., Kong, X., Goldberg, M. P., Stowe, A. M., &
Raman, L. (2015). Erythropoietin-mediated neuroprotection
in a pediatric mouse model of chronic hypoxia. Neurosci
Lett, 597, 54–59.
Collino, M., Thiemermann, C., Cerami, A., & Brines, M.
(2015). Flipping the molecular switch for innate protection
and repair of tissues: Long-lasting effects of a non-
erythropoietic small peptide engineered from erythropoietin.
Pharmacol Ther, 151, 32–40.
Constantinescu, S. N., Ghaffari, S., & Lodish, H. F. (1999). The
erythropoietin receptor: Structure, activation and intracellu-
lar signal transduction. Trends Endocrinol Metab, 10, 18–23.
Coppede`, F. (2014). The potential of epigenetic therapies in
neurodegenerative diseases. Front Genet, 5, 220.
Costa, D. D., Beghi, E., Carignano, P., Pagliacci, C., Faccioli,
F., Pupillo, E., Messina, P., Gorio, A., & Redaelli, T. (2015).
Tolerability and efficacy of erythropoietin (EPO) treatment
in traumatic spinal cord injury: A preliminary randomized
comparative trial vs. methylprednisolone (MP). Neurol Sci,
36, 1567–1574.
Culver, D. A., Dahan, A., Bajorunas, D., Jeziorska, M., van
Velzen, M., Aarts, L. P. H. J., Tavee, J., Tannemaat, M. R.,
Dunne, A. N., Kirk, R. I., Petropoulos, I. N., Cerami, A.,
Malik, R. A., & Brines, M. (2017). Cibinetide improves cor-
neal nerve fiber abundance in patients with sarcoidosis-
associated small nerve fiber loss and neuropathic pain.
Invest Ophthalmol Vis Sci, 58, BIO52–BIO60.
Dang, J., Jia, R., Tu, Y., Xiao, S., & Ding, G. (2010).
Erythropoietin prevents reactive oxygen species generation
and renal tubular cell apoptosis at high glucose level. Biomed
Pharmacother, 64, 681–685.
Darnell, J. E., Kerr, I. M., & Stark, G. R. (1994). Jak-STAT
pathways and transcriptional activation in response to IFNs
and other extracellular signaling proteins. Science,
264, 1415–1421.
De, S. R., Ajmone-Cat, M. A., Nicolini, A., & Minghetti, L.
(2002). Expression of phosphatidylserine receptor and
down-regulation of pro-inflammatory molecule production
by its natural ligand in rat microglial cultures. J Neuropathol
Exp Neurol, 61, 237–244.
de Vos, A. M., Ultsch, M., & Kossiakoff, A. A. (1992). Human
growth hormone and extracellular domain of its receptor:
Crystal structure of the complex. Science, 255, 306–312.
Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H.,
Rivas, L. A., Bauer, C., & Gassmann, M. (1995).
Localization of specific erythropoietin binding sites
in defined areas of the mouse brain. Proc Natl Acad Sci
U S A, 92, 3717–3720.
Digicaylioglu, M., & Lipton, S. A. (2001). Erythropoietin-
mediated neuroprotection involves cross-talk between Jak2
and NF-kappaB signalling cascades. Nature, 412, 641–647.
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999).
Pathobiology of ischaemic stroke: An integrated view.
Trends Neurosci, 22, 391–397.
Donati, A., Damiani, E., Zuccari, S., Domizi, R., Scorcella, C.,
Girardis, M., Giulietti, A., Vignini, A., Adrario, E.,
Romano, R., Mazzanti, L., Pelaia, P., & Singer, M.
(2017). Effects of short-term hyperoxia on erythropoietin
levels and microcirculation in critically Ill patients: A pro-
spective observational pilot study. BMC Anesthesiol, 17, 49.
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L.,
Lewczuk, P., Stiefel, M., Bohn, M. (2002). Erythropoietin
therapy for acute stroke is both safe and beneficial. Mol
Med, 8, 495–505.
Erbas¸, O., C¸ınar, B. P., Solmaz, V., C¸avus¸oglu, T., & Ates¸, U.
(2015). The neuroprotective effect of erythropoietin on
experimental Parkinson model in rats. Neuropeptides,
49, 1–5.
Esmaeili Tazangi, P., Moosavi, S. M., Shabani, M., & Haghani,
M. (2015). Erythropoietin improves synaptic plasticity and
memory deficits by decrease of the neurotransmitter release
Rey et al. 13
probability in the rat model of Alzheimer’s disease.
Pharmacol Biochem Behav, 130, 15–21.
Fantacci, M., Bianciardi, P., Caretti, A., Coleman, T. R.,
Cerami, A., Brines, M., & Samaja, M. (2006).
Carbamylated erythropoietin ameliorates the metabolic
stress induced in vivo by severe chronic hypoxia. Proc Natl
Acad Sci U S A, 103, 17531–17536.
Fletcher, J. W., Gallagher, N. I., Warnecke, M. A., & Donati,
R. M. (1973). Erythropoiesis and hyperoxia. Proc Soc Exp
Biol Med, 144, 569–574.
Furlan, J. C., Noonan, V., Cadotte, D. W., & Fehlings, M. G.
(2011). Timing of decompressive surgery of spinal cord after
traumatic spinal cord injury: An evidence-based examina-
tion of pre-clinical and clinical studies. J Neurotrauma,
28, 1371–1399.
Gao, Z., Ure, K., Ding, P., Nashaat, M., Yuan, L., Ma, J.,
Hammer, R. E., & Hsieh, J. (2011). The master negative
regulator REST/NRSF controls adult neurogenesis by
restraining the neurogenic program in quiescent stem cells.
J Neurosci, 31, 9772–9786.
Gonzalez, F. F., Larpthaveesarp, A., McQuillen, P., Derugin,
N., Wendland, M., Spadafora, R., & Ferriero, D. M. (2013).
Erythropoietin increases neurogenesis and oligodendroglio-
sis of subventricular zone precursor cells after neonatal
stroke. Stroke, 44, 753–758.
Gorio, A., Gokmen, N., Erbayraktar, S., Yilmaz, O.,
Madaschi, L., Cichetti, C., Di Giulio, A. M., Vardar, E.,
Cerami, A., & Brines, M. (2002). Recombinant human
erythropoietin counteracts secondary injury and markedly
enhances neurological recovery from experimental spinal
cord trauma. Proc Natl Acad Sci U S A, 99, 9450–9455.
Gorio, A., Madaschi, L., Di Stefano, B., Carelli, S., Di Giulio,
A. M., De Biasi, S., Coleman, T., Cerami, A., & Brines, M.
(2005). Methylprednisolone neutralizes the beneficial effects
of erythropoietin in experimental spinal cord injury. Proc
Natl Acad Sci U S A, 102, 16379–16384.
Grignaschi, G., Zennaro, E., Tortarolo, M., Calvaresi, N., &
Bendotti, C. (2007). Erythropoietin does not preserve motor
neurons in a mouse model of familial ALS. Amyotroph
Lateral Scler, 8, 31–35.
Grimm, C., Wenzel, A., Groszer, M., Mayser, H., Seeliger, M.,
Samardzija, M., Bauer, C., Gassmann, M., & Reme´, C. E.
(2002). HIF-1-induced erythropoietin in the hypoxic retina
protects against light-induced retinal degeneration. Nat
Med, 8, 718–724.
Grimm, G., Stockenhuber, F., Schneeweiss, B., Madl, C.,
Zeitlhofer, J., & Schneider, B. (1990). Improvement of
brain function in hemodialysis patients treated with erythro-
poietin. Kidney Int, 38, 480–486.
Gre´goire, C. A., Goldenstein, B. L., Floriddia, E. M., Barnabe´-
Heider, F., & Fernandes, K. J. (2015). Endogenous neural
stem cell responses to stroke and spinal cord injury. Glia,
63, 1469–1482.
Grunfeld, J. F., Barhum, Y., Blondheim, N., Rabey, J. M.,
Melamed, E., & Offen, D. (2007). Erythropoietin delays dis-
ease onset in an amyotrophic lateral sclerosis model. Exp
Neurol, 204, 260–263.
Gunnarson, E., Song, Y., Kowalewski, J. M., Brismar, H.,
Brines, M., Cerami, A., Andersson, U., Zelenina, M., &
Aperia, A. (2009). Erythropoietin modulation of astrocyte
water permeability as a component of neuroprotection. Proc
Natl Acad Sci U S A, 106, 1602–1607.
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L.,
Mansfield, K. D., Simon, M. C., Hammerling, U., &
Schumacker, P. T. (2005). Mitochondrial complex III is
required for hypoxia-induced ROS production and cellular
oxygen sensing. Cell Metab, 1, 401–408.
Gyongyosi, A., Terraneo, L., Bianciardi, P., Tosaki, A., Lekli,
I., & Samaja, M. (2018). The impact of moderate chronic
hypoxia and hyperoxia on the level of apoptotic and auto-
phagic proteins in myocardial tissue. Oxid Med Cell Longev,
2018, 5786742.
Haase, V. H. (2013). Regulation of erythropoiesis by hypoxia-
inducible factors. Blood Rev, 27, 41–53.
Hassouna I, et al. (2016). Revisiting adult neurogenesis and the
role of erythropoietin for neuronal and oligodendroglial dif-
ferentiation in the hippocampus. Mol Psychiatry,
21, 1752–1767.
Herna´ndez, C. C., Burgos, C. F., Gajardo, A. H., Silva-
Grecchi, T., Gavilan, J., Toledo, J. R., & Fuentealba, J.
(2017). Neuroprotective effects of erythropoietin on neuro-
degenerative and ischemic brain diseases: The role of eryth-
ropoietin receptor. Neural Regen Res, 12, 1381–1389.
Hock, N. H. (1998). Neuroprotective agents in acute ischemic
stroke. J Cardiovasc Nurs, 13, 17–25.
Jang, W., Kim, H. J., Li, H., Jo, K. D., Lee, M. K., & Yang,
H. O. (2016). The neuroprotective effect of erythropoietin
on rotenone-induced neurotoxicity in SH-SY5Y cells
through the induction of autophagy. Mol Neurobiol,
53, 3812–3821.
Jang, W., Park, J., Shin, K. J., Kim, J. S., Youn, J., Cho, J. W.,
Oh, E., Ahn, J. Y., Oh, K. W., & Kim, H. T. (2014). Safety
and efficacy of recombinant human erythropoietin treatment
of non-motor symptoms in Parkinson’s disease. J Neurol
Sci, 337, 47–54.
Jelkmann, W. (2001). The role of the liver in the production of
thrombopoietin compared with erythropoietin. Eur J
Gastroenterol Hepatol, 13, 791–801.
Jelkmann, W. (2007). Erythropoietin after a century of
research: Younger than ever. Eur J Haematol, 78, 183–205.
Jelkmann, W. (2016). Erythropoietin. Front Horm Res,
47, 115–127.
Jia, Y., Mo, S. J., Feng, Q. Q., Zhan, M. L., OuYang, L. S.,
Chen, J. C., Ma, Y. X., Wu, J. J., & Lei, W. L. (2014). EPO-
dependent activation of PI3K/Akt/FoxO3a signalling medi-
ates neuroprotection in in vitro and in vivo models of
Parkinson’s disease. J Mol Neurosci, 53, 117–124.
Juul, S. E., Yachnis, A. T., Rojiani, A. M., & Christensen,
R. D. (1999). Immunohistochemical localization of erythro-
poietin and its receptor in the developing human brain.
Pediatr Dev Pathol, 2, 148–158.
Kaelin, W. G., Jr. (2005). ROS: Really involved in oxygen sens-
ing. Cell Metabol, 1, 357–358.
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014).
Alzheimer’s disease genetics: From the bench to the clinic.
Neuron, 83, 11–26.
Kato, S., Aoyama, M., Kakita, H., Hida, H., Kato, I., Ito, T.,
Goto, T., Hussein, M. H., Sawamoto, K., Togari, H., &
14 ASN Neuro
Asai, K. (2011). Endogenous erythropoietin from astrocyte
protects the oligodendrocyte precursor cell against hypoxic
and reoxygenation injury. J Neurosci Res, 89, 1566–1574.
Keswani, S. C., Bosch-Marce´, M., Reed, N., Fischer, A.,
Semenza, G. L., & H€oke, A. (2011). Nitric oxide prevents
axonal degeneration by inducing HIF-1-dependent expres-
sion of erythropoietin. Proc Natl Acad Sci U S A,
108, 4986–4990.
Kiboub, F. Z., Balestra, C., Loennechen, O., & Eftedal, I.
(2018). Hemoglobin and erythropoietin after commercial
saturation diving. Front Physiol, 9, 1176.
Kim, G. H., Kim, J. E., Rhie, S. J., & Yoon, S. (2015). The role
of oxidative stress in neurodegenerative diseases. Exp
Neurobiol, 24, 325–340.
Kim, H. Y., Moon, C., Kim, K. S., Oh, K. W., Oh, S. I., Kim,
J., & Kim, S. H. (2014). Recombinant human erythropoietin
in amyotrophic lateral sclerosis: A pilot study of safety and
feasibility. J Clin Neurol, 10, 342–347.
King, V. R., Averill, S. A., Hewazy, D., Priestley, J. V., Torup,
L., & Michael-Titus, A. T. (2007). Erythropoietin and car-
bamylated erythropoietin are neuroprotective following
spinal cord hemisection in the rat. Eur J Neurosci,
26, 90–100.
Koh, S. H., Kim, Y., Kim, H. Y., Cho, G. W., Kim, K. S., &
Kim, S. H. (2007). Recombinant human erythropoietin sup-
presses symptom onset and progression of G93A-SOD1
mouse model of ALS by preventing motor neuron death
and inflammation. Eur J Neurosci, 25, 1923–1930.
Kokot, F., Franek, E., Kokot, M., & Wiecek, A. (1994a).
Erythropoietin secretion in patients with chronic renal fail-
ure after pure oxygen breathing. Nephron, 67, 436–440.
Kokot, M., Kokot, F., Franek, E., Wiecek, A., Nowicki, M., &
Dulawa, J. (1994b). Effect of isobaric hyperoxemia on eryth-
ropoietin secretion in hypertensive patients. Hypertension,
24, 486–490.
Kumagai, R., Koike, M., Iwase, Y., & Ichimiya, Y. (2018).
Erythropoietin preparation drastically improved activities
of daily living in a patient with severe dementia. Psychiatry
Clin Neurosci, 72, 849.
Lauria, G., Campanella, A., Filippini, G., Martini, A., Penza,
P., Maggi, L., Antozzi, C., Ciano, C., Beretta, P., Caldiroli,
D., Ghelma, F., Ferrara, G., Ghezzi, P., & Mantegazza, R.
(2009). Erythropoietin in amyotrophic lateral sclerosis:
A pilot, randomized, double-blind, placebo-controlled
study of safety and tolerability. Amyotroph Lateral Scler,
10, 410–415.
Lauria, G., et al. (2015). Erythropoietin in amyotrophic lateral
sclerosis: A multicentre, randomised, double blind, placebo
controlled, phase III study. J Neurol Neurosurg Psychiatry,
86, 879–886.
Law, M. L., Cai, G. Y., Lin, F. K., Wei, Q., Huang, S. Z.,
Hartz, J. H., Morse, H., Lin, C. H., Jones, C., & Kao,
F. T. (1986). Chromosomal assignment of the human eryth-
ropoietin gene and its DNA polymorphism. Proc Natl Acad
Sci U S A, 83, 6920–6924.
Lee, C. S., Lee, C., Hu, T., Nguyen, J. M., Zhang, J., Martin,
M. V., Vawter, M. P., Huang, E. J., & Chan, J. Y. (2011).
Loss of nuclear factor E2-related factor 1 in the brain leads
to dysregulation of proteasome gene expression and neuro-
degeneration. Proc Natl Acad Sci U S A, 108, 8408–8413.
Lee, S. T., Chu, K., Park, J. E., Jung, K. H., Jeon, D., Lim,
J. Y., Lee, S. K., Kim, M., & Roh, J. K. (2012).
Erythropoietin improves memory function with reducing
endothelial dysfunction and amyloid-beta burden in
Alzheimer’s disease models. J Neurochem, 120, 115–124.
Leist, M., et al. (2004). Derivatives of erythropoietin that are
tissue protective but not erythropoietic. Science, 305, 239–242.
Lewczuk, P., Hasselblatt, M., Kamrowski-Kruck, H., Heyer,
A., Unzicker, C., Siren, A. L., & Ehrenreich, H. (2000).
Survival of hippocampal neurons in culture upon hypoxia:
Effect of erythropoietin. Neuroreport, 11, 3485–3488.
Li, G., Ma, R., Huang, C., Tang, Q., Fu, Q., Liu, H., Hu, B., &
Xiang, J. (2008). Protective effect of erythropoietin on beta-
amyloid-induced PC12 cell death through antioxidant mech-
anisms. Neurosci Lett, 442, 143–147.
Li, Y. P., Yang, G. J., Jin, L., Yang, H. M., Chen, J., Chai,
G. S., & Wang, L. (2015). Erythropoietin attenuates
Alzheimer-like memory impairments and pathological
changes induced by amyloid b42 in mice. Brain Res,
1618, 159–167.
Liu, E. Y., Cali, C. P., & Lee, E. B. (2017a). RNA metabolism
in neurodegenerative disease. Dis Model Mech, 10, 509–518.
Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L.
(2017b). Oxidative stress in neurodegenerative diseases:
From molecular mechanisms to clinical applications. Oxid
Med Cell Longev, 2017, 2525967.
Lombardero, M., Kovacs, K., & Scheithauer, B. W. (2011).
Erythropoietin: A hormone with multiple functions.
Pathobiology, 78, 41–53.
Ma, R., Xiong, N., Huang, C., Tang, Q., Hu, B., Xiang, J., &
Li, G. (2009). Erythropoietin protects PC12 cells from beta-
amyloid(25-35)-induced apoptosis via PI3K/Akt signaling
pathway. Neuropharmacology, 56, 1027–1034.
Madav, Y., Wairkar, S., & Prabhakar, B. (2019). Recent ther-
apeutic strategies targeting beta amyloid and tauopathies in
Alzheimer’s disease. Brain Res Bull, 146, 171–184.
Maiese, K., Chong, Z. Z., Shang, Y. C., & Wang, S. (2012).
Erythropoietin: New directions for the nervous system. Int J
Mol Sci, 13, 11102–11129.
Marconi, G. D., Zara, S., De Colli, M., Di Valerio, V., Rapino,
M., Zaramella, P., Dedja, A., Macchi, V., De Caro, R., &
Porzionato, A. (2014). Postnatal hyperoxia exposure differ-
entially affects hepatocytes and liver haemopoietic cells in
newborn rats. PLoS One, 9, e105005.
Marcuzzi, F., Zucchelli, S., Bertuzzi, M., Santoro, C., Tell, G.,
Carninci, P., & Gustincich, S. (2016). Isoforms of the eryth-
ropoietin receptor in dopaminergic neurons of the substantia
nigra. J Neurochem, 139, 596–609.
Marfia, G., Madaschi, L., Marra, F., Menarini, M., Bottai, D.,
Formenti, A., Bellardita, C., Di Giulio, A. M., Carelli, S., &
Gorio, A. (2011). Adult neural precursors isolated from post
mortem brain yield mostly neurons: An erythropoietin-
dependent process. Neurobiol Dis, 43, 86–98.
Marti, H. H. (2004). Erythropoietin and the hypoxic brain.
J Exp Biol, 207, 3233–3242.
Marti, H. H., Wenger, R. H., Rivas, L. A., Straumann, U.,
Digicaylioglu, M., Henn, V., Yonekawa, Y., Bauer, C., &
Rey et al. 15
Gassmann, M. (1996). Erythropoietin gene expression in
human, monkey and murine brain. Eur J Neurosci,
8, 666–676.
Martino, G., & Pluchino, S. (2006). The therapeutic potential of
neural stem cells. Nat Rev Neurosci, 7, 395–406.
Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M.,
& Sasaki, R. (1994). A novel site of erythropoietin produc-
tion. Oxygen-dependent production in cultured rat astro-
cytes. J Biol Chem, 269, 19488–19493.
Matthews, D. J., Topping, R. S., Cass, R. T., & Giebel, L. B.
(1996). A sequential dimerization mechanism for erythropoi-
etin receptor activation. Proc Natl Acad Sci U S A,
93, 9471–9476.
Maurice, T., Mustafa, M. H., Desrumaux, C., Keller, E., Naert,
G., de la, C., Garcıa-Barcelo, M., Rodrıguez Cruz, Y., &
Garcia Rodrıguez, J. C. (2013). Intranasal formulation of
erythropoietin (EPO) showed potent protective activity
against amyloid toxicity in the Ab25-35 non-transgenic
mouse model of Alzheimer’s disease. J Psychopharmacol,
27, 1044–1057.
Merelli, A., Czornyj, L., & Lazarowski, A. (2015).
Erythropoietin as a new therapeutic opportunity in brain
inflammation and neurodegenerative diseases. Int J
Neurosci, 125, 793–797.
Mofidi, A., Bader, A., & Pavlica, S. (2011). The use of eryth-
ropoietin and its derivatives to treat spinal cord injury. Mini
Rev Med Chem, 11, 763–770.
Momeni, M., De Kock, M., Devuyst, O., & Liistro, G. (2011).
Effect of N-acetyl-cysteine and hyperoxia on erythropoietin
production. Eur J Appl Physiol, 111, 2681–2686.
Naganska, E., Taraszewska, A., Matyja, E., Grieb, P., &
Rafałowska, J. (2010). Neuroprotective effect of erythropoi-
etin in amyotrophic lateral sclerosis (ALS) model in vitro.
Ultrastructural study. Folia Neuropathol, 48, 35–44.
Nekoui, A., & Blaise, G. (2017). Erythropoietin and nonhema-
topoietic effects. Am J Med Sci, 353, 76–81.
Ng, T., Marx, G., Littlewood, T., & Macdougall, I. (2003).
Recombinant erythropoietin in clinical practice. Postgrad
Med J, 79, 367–376.
Noh, M. Y., Cho, K. A., Kim, H., Kim, S. M., & Kim, S. H.
(2014). Erythropoietin modulates the immune-inflammatory
response of a SOD1(G93A) transgenic mouse model of
amyotrophic lateral sclerosis (ALS). Neurosci Lett,
574, 53–58.
Nutt, J. G., & Wooten, G. F. (2005). Clinical practice.
Diagnosis and initial management of Parkinson’s disease.
N Engl J Med, 353, 1021–1027.
Ogilvie, M., Yu, X., Nicolas-Metral, V., Pulido, S. M., Liu, C.,
Ruegg, U. T., & Noguchi, C. T. (2000). Erythropoietin stim-
ulates proliferation and interferes with differentiation of
myoblasts. J Biol Chem, 275, 39754–39761.
Osredkar, D., Sall, J. W., Bickler, P. E., & Ferriero, D. M.
(2010). Erythropoietin promotes hippocampal neurogenesis
in in vitro models of neonatal stroke. Neurobiol Dis,
38, 259–265.
Ostrowski, D., & Heinrich, R. (2018). Alternative erythropoie-
tin receptors in the nervous system. J Clin Med, 7, 24.
Pedroso, I., Bringas, M. L., Aguiar, A., Morales, L., Alvarez,
M., Valde´s, P. A., & Alvarez, L. (2012). Use of Cuban
recombinant human erythropoietin in Parkinson’s disease
treatment. MEDICC Rev, 14, 11–17.
Perreault, A. A., Benton, M. L., Koury, M. J., Brandt, S. J., &
Venters, B. J. (2017). Epo reprograms the epigenome of ery-
throid cells. Exp Hematol, 51, 47–62.
Piguet, F., Alves, S., & Cartier, N. (2017). Clinical gene therapy
for neurodegenerative diseases: Past, present, and future.
Hum Gene Ther, 28, 988–1003.
Ponce, L. L., Navarro, J. C., Ahmed, O., & Robertson, C. S.
(2013). Erythropoietin neuroprotection with traumatic brain
injury. Pathophysiology, 20, 31–38.
Profyris, C., Cheema, S. S., Zang, D., Azari, M. F., Boyle, K., &
Petratos, S. (2004). Degenerative and regenerative mechanisms
governing spinal cord injury. Neurobiol Dis, 15, 415–436.
Qi, C., Xu, M., Gan, J., Yang, X., Wu, N., Song, L., Yuan, W.,
& Liu, Z. (2014). Erythropoietin improves neurobehavior by
reducing dopaminergic neuron loss in a 6-hydroxydop-
amine-induced rat model. Int J Mol Med, 34, 440–450.
Rabie, T., & Marti, H. H. (2008). Brain protection by erythro-
poietin: A manifold task. Physiology (Bethesda),
23, 263–274.
Rees, S., Hale, N., De Matteo, R., Cardamone, L., Tolcos, M.,
Loeliger, M., Mackintosh, A., Shields, A., Probyn, M.,
Greenwood, D., & Harding, R. (2010). Erythropoietin is neu-
roprotective in a preterm ovine model of endotoxin-induced
brain injury. J Neuropathol Exp Neurol, 69, 306–319.
Richmond, T. D., Chohan, M., & Barber, D. L. (2005). Turning
cells red: Signal transduction mediated by erythropoietin.
Trends Cell Biol, 15, 146–155.
Rocco, M., D’Itri, L., De Bels, D., Corazza, F., & Balestra, C.
(2014). The “normobaric oxygen paradox”: A new tool for
the anesthetist? Minerva Anestesiol, 80, 366–372.
Rodrıguez Cruz, Y., Strehaiano, M., Rodrıguez Obaya, T.,
Garcıa Rodrıguez, J. C., & Maurice, T. (2017). An intrana-
sal formulation of erythropoietin (Neuro-EPO) prevents
memory deficits and amyloid toxicity in the APPSwe trans-
genic mouse model of Alzheimer’s disease. J Alzheimers Dis,
55, 231–248.
Romanko, M. J., Zhu, C., Bahr, B. A., Blomgren, K., &
Levison, S. W. (2007). Death effector activation in the sub-
ventricular zone subsequent to perinatal hypoxia/ischemia.
J Neurochem, 103, 1121–1131.
Rothwell, N. J., & Hopkins, S. J. (1995). Cytokines and the
nervous system II: Actions and mechanisms of action.
Trends Neurosci, 18, 130–136.
Ruscher, K., Isaev, N., Trendelenburg, G., Weih, M., Iurato,
L., Meisel, A., & Dirnagl, U. (1998). Induction of hypoxia
inducible factor 1 by oxygen glucose deprivation is attenu-
ated by hypoxic preconditioning in rat cultured neurons.
Neurosci Lett, 254, 117–120.
Sakanaka, M., Wen, T. C., Matsuda, S., Masuda, S., Morishita,
E., Nagao, M., & Sasaki, R. (1998). In vivo evidence that
erythropoietin protects neurons from ischemic damage. Proc
Natl Acad Sci U S A, 95, 4635–4640.
Sakthiswary, R., & Raymond, A. A. (2012). Stem cell therapy
in neurodegenerative diseases: From principles to practice.
Neural Regen Res, 7, 1822–1831.
Salta, E., & De Strooper, B. (2017). Noncoding RNAs in neuro-
degeneration. Nat Rev Neurosci, 18, 627–640.
16 ASN Neuro
Samy, D. M., Ismail, C. A., Nassra, R. A., Zeitoun, T. M., &
Nomair, A. M. (2016). Downstream modulation of extrinsic
apoptotic pathway in streptozotocin-induced Alzheimer’s
dementia in rats: Erythropoietin versus curcumin. Eur J
Pharmacol, 770, 52–60.
Sanchez, P. E., Fares, R. P., Risso, J. J., Bonnet, C., Bouvard,
S., Le-Cavorsin, M., Georges, B., Moulin, C., Belmeguenai,
A., Bodennec, J., Morales, A., Pequignot, J. M., Baulieu,
E. E., Levine, R. A., & Bezin, L. (2009). Optimal neuro-
protection by erythropoietin requires elevated expression
of its receptor in neurons. Proc Natl Acad Sci U S A,
106, 9848–9853.
Sanchis-Gomar, F., Garcia-Gimenez, J. L., Pareja-Galeano, H.,
Romagnoli, M., Perez-Quilis, C., & Lippi, G. (2014).
Erythropoietin and the heart: Physiological effects and the
therapeutic perspective. Int J Cardiol, 171, 116–125.
Sargin, D., El-Kordi, A., Agarwal, A., Mu¨ller, M., Wojcik,
S. M., Hassouna, I., Sperling, S., Nave, K. A., &
Ehrenreich, H. (2011). Expression of constitutively active
erythropoietin receptor in pyramidal neurons of cortex and
hippocampus boosts higher cognitive functions in mice.
BMC Biol, 9, 27.
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis,
S. E. (1991). Hypoxia-inducible nuclear factors bind to an
enhancer element located 3’ to the human erythropoietin
gene. Proc Natl Acad Sci U S A, 88, 5680–5684.
Semenza, G. L., & Wang, G. L. (1992). A nuclear factor
induced by hypoxia via de novo protein synthesis binds to
the human erythropoietin gene enhancer at a site required
for transcriptional activation. Mol Cell Biol, 12, 5447–5454.
Shang, Y. C., Chong, Z. Z., Wang, S., & Maiese, K. (2011).
Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-
1, and XIAP in inflammatory microglia. Curr Neurovasc
Res, 8, 270–285.
Shang, Y. C., Chong, Z. Z., Wang, S., & Maiese, K. (2012).
Prevention of b-amyloid degeneration of microglia by eryth-
ropoietin depends on Wnt1, the PI 3-K/mTOR pathway,
Bad, and Bcl-xL. Aging (Albany NY), 4, 187–201.
Shingo, T., Sorokan, S. T., Shimazaki, T., & Weiss, S. (2001).
Erythropoietin regulates the in vitro and in vivo production
of neuronal progenitors by mammalian forebrain neural
stem cells. J Neurosci, 21, 9733–9743.
Simon, F., Scheuerle, A., Gr€oger, M., Vcelar, B., McCook, O.,
M€oller, P., Georgieff, M., Calzia, E., Radermacher, P., &
Schelzig, H. (2011). Comparison of carbamylated
erythropoietin-FC fusion protein and recombinant human
erythropoietin during porcine aortic balloon occlusion-
induced spinal cord ischemia/reperfusion injury. Intensive
Care Med, 37, 1525–1533.
Simon, F. H., Erhart, P., Vcelar, B., Scheuerle, A., Schelzig, H.,
& Oberhuber, A. (2016). Erythropoietin preconditioning
improves clinical and histologic outcome in an acute spinal
cord ischemia and reperfusion rabbit model. J Vasc Surg,
64, 1797–1804.
Soliz, J., Gassmann, M., & Joseph, V. (2007). Soluble erythro-
poietin receptor is present in the mouse brain and is required
for the ventilatory acclimatization to hypoxia. J Physiol,
583, 329–336.
Sollinger, C., Lillis, J., Malik, J., Getman, M., Proschel, C., &
Steiner, L. (2017). Erythropoietin signaling regulates key
epigenetic and transcription networks in fetal neural progen-
itor cells. Sci Rep, 7, 14381.
Studer, L., Csete, M., Lee, S. H., Kabbani, N., Walikonis, J.,
Wold, B., & McKay, R. (2000). Enhanced proliferation, sur-
vival, and dopaminergic differentiation of CNS precursors in
lowered oxygen. J Neurosci, 20, 7377–7383.
Sugawa, M., Sakurai, Y., Ishikawa-Ieda, Y., Suzuki, H., &
Asou, H. (2002). Effects of erythropoietin on glial cell devel-
opment; oligodendrocyte maturation and astrocyte prolifer-
ation. Neurosci Res, 44, 391–403.
Sun, J., Martin, J. M., Vanderpoel, V., & Sumbria, R. K.
(2019). The promises and challenges of erythropoietin for
treatment of Alzheimer’s disease. Neuromolecular Med,
21, 12–24.
Suzuki, S., Tanaka, K., Nogawa, S., Dembo, T., Kosakai, A., &
Fukuuchi, Y. (2001). Phosphorylation of signal transducer
and activator of transcription-3 (Stat3) after focal cerebral
ischemia in rats. Exp Neurol, 170, 63–71.
Tang, Z., Sun, X., Huo, G., Xie, Y., Shi, Q., Chen, S., Wang,
X., & Liao, Z. (2013). Protective effects of erythropoietin on
astrocytic swelling after oxygen-glucose deprivation and
reoxygenation: Mediation through AQP4 expression and
MAPK pathway. Neuropharmacology, 67, 8–15.
Temple, R. M., Deary, I. J., & Winney, R. J. (1995).
Recombinant erythropoietin improves cognitive function in
patients maintained on chronic ambulatory peritoneal dial-
ysis. Nephrol Dial Transplant, 10, 1733–1738.
Terraneo, L., Paroni, R., Bianciardi, P., Giallongo, T., Carelli,
S., Gorio, A., & Samaja, M. (2017). Brain adaptation to
hypoxia and hyperoxia in mice. Redox Biol, 11, 12–20.
Terraneo, L., & Samaja, M. (2017). Comparative response of
brain to chronic hypoxia and hyperoxia. Int J Mol Sci,
18, 1914.
Terraneo, L., Virgili, E., Caretti, A., Bianciardi, P., & Samaja,
M. (2014). In vivo hyperoxia induces hypoxia-inducible
factor-1alpha overexpression in LNCaP tumors without
affecting the tumor growth rate. Int J Biochem Cell Biol,
51C, 65–74.
Tsai, T. H., Lu, C. H., Wallace, C. G., Chang, W. N., Chen,
S. F., Huang, C. R., Tsai, N. W., Lan, M. Y., Sung, P. H.,
Liu, C. F., & Yip, H. K. (2015). Erythropoietin improves
long-term neurological outcome in acute ischemic stroke
patients: A randomized, prospective, placebo-controlled
clinical trial. Crit Care, 19, 49.
Tsuda, E., Goto, M., Murakami, A., Akai, K., Ueda, M.,
Kawanishi, G., Takahashi, N., Sasaki, R., Chiba, H., &
Ishihara, H. (1988). Comparative structural study of N-
linked oligosaccharides of urinary and recombinant erythro-
poietins. Biochemistry, 27, 5646–5654.
Tysnes, O. B., & Storstein, A. (2017). Epidemiology of
Parkinson’s disease. J Neural Transm (Vienna),
124, 901–905.
Vinothkumar, G., Krishnakumar, S., Sureshkumar,
Shivashekar, G., Sreedhar, S., Preethikrishnan, Dinesh, S.,
Sundaram, A., Balakrishnan, D., Riya, & Venkataraman, P.
(2018) Therapeutic impact of rHuEPO on abnormal platelet
APP, BACE 1, presenilin 1, ADAM 10 and Ab expressions
Rey et al. 17
in chronic kidney disease patients with cognitive dysfunction
like Alzheimer’s disease: A pilot study. Biomed
Pharmacother, 104, 211–222.
Viviani, B., Bartesaghi, S., Corsini, E., Villa, P., Ghezzi, P.,
Garau, A., Galli, C. L., & Marinovich, M. (2005).
Erythropoietin protects primary hippocampal neurons
increasing the expression of brain-derived neurotrophic
factor. J Neurochem, 93, 412–421.
Wang, L., Zhang, Z., Wang, Y., Zhang, R., & Chopp, M.
(2004). Treatment of stroke with erythropoietin enhances
neurogenesis and angiogenesis and improves neurological
function in rats. Stroke, 35, 1732–1737.
Wang, W., Kagaya, Y., Asaumi, Y., Fukui, S., Takeda, M., &
Shimokawa, H. (2011). Protective effects of recombinant
human erythropoietin against pressure overload-induced
left ventricular remodeling and premature death in mice.
Tohoku J Exp Med, 225, 131–143.
Weishaupt, J. H., Rohde, G., P€olking, E., Siren, A. L.,
Ehrenreich, H., & B€ahr, M. (2004). Effect of erythropoietin
axotomy-induced apoptosis in rat retinal ganglion cells.
Invest Ophthalmol Vis Sci, 45, 1514–1522.
Widl, K., Brettschneider, J., Schattauer, D., Su¨ssmuth, S.,
Huber, R., Ludolph, A. C., & Tumani, H. (2007).
Erythropoietin in cerebrospinal fluid: Age-related reference
values and relevance in neurological disease. Neurochem Res,
32, 1163–1168.
Wijesekera, L. C., & Leigh, P. N. (2009). Amyotrophic lateral
sclerosis. Orphanet J Rare Dis, 4, 3.
Wikenheiser, J., Wolfram, J. A., Gargesha, M., Yang, K.,
Karunamuni, G., Wilson, D. L., Semenza, G. L., Agani,
F., Fisher, S. A., Ward, N., & Watanabe, M. (2009).
Altered hypoxia-inducible factor-1 alpha expression levels
correlate with coronary vessel anomalies. Dev Dyn,
238, 2688–2700.
Wirdefeldt, K., Adami, H. O., Cole, P., Trichopoulos, D., &
Mandel, J. (2011). Epidemiology and etiology of Parkinson’s
disease: A review of the evidence. Eur J Epidemiol, 26(Suppl
1), S1–S58.
Wu, X. M., Qian, C., Zhou, Y. F., Yan, Y. C., Luo, Q. Q.,
Yung, W. H., Zhang, F. L., Jiang, L. R., Qian, Z. M., & Ke,
Y. (2017). Bi-directionally protective communication
between neurons and astrocytes under ischemia. Redox
Biol, 13, 20–31.
Wu, Y., Shang, Y., Sun, S. G., Liu, R. G., & Yang, W. Q.
(2007). Protective effect of erythropoietin against 1-methyl-
4-phenylpyridinium-induced neurodegenaration in PC12
cells. Neurosci Bull, 23, 156–164.
Yao, X., Wang, D., Li, H., Shen, H., Shu, Z., & Chen, G.
(2017). Erythropoietin treatment in patients with acute
ischemic stroke: A systematic review and meta-analysis of
randomized controlled trials. Curr Drug Deliv, 14, 853–860.
Yoo, S. J., Cho, B., Lee, D., Son, G., Lee, Y. B., Soo Han, H.,
Kim, E., & Moon, C. (2017). The erythropoietin-derived
peptide MK-X and erythropoietin have neuroprotective
effects against ischemic brain damage. Cell Death Dis,
8, e3003.
Yu, X., Shacka, J. J., Eells, J. B., Suarez-Quian, C., Przygodzki,
R. M., Beleslin-Cokic, B., Lin, C. S., Nikodem, V. M.,
Hempstead, B., Flanders, K. C., Costantini, F., &
Noguchi, C. T. (2002). Erythropoietin receptor signalling is
required for normal brain development. Development,
129, 505–516.
Zara, S., Macchi, V., De Caro, R., Rapino, M., Cataldi, A., &
Porzionato, A. (2012). pPKCalpha mediated-HIF-1alpha
activation related to the morphological modifications occur-
ring in neonatal myocardial tissue in response to severe and
mild hyperoxia. Eur J Histochem, 56, e2.
Zhang, H., Fang, X., Huang, D., Luo, Q., Zheng, M., Wang,
K., Cao, L., & Yin, Z. (2018). Erythropoietin signaling
increases neurogenesis and oligodendrogenesis of endoge-
nous neural stem cells following spinal cord injury both
in vivo and in vitro. Mol Med Rep, 17, 264–272.
Zhu, C., Kang, W., Xu, F., Cheng, X., Zhang, Z., Jia, L., Ji, L.,
Guo, X., Xiong, H., Simbruner, G., Blomgren, K., & Wang,
X. (2009). Erythropoietin improved neurologic outcomes in
newborns with hypoxic-ischemic encephalopathy. Pediatrics,
124, e218–226.
18 ASN Neuro
